Photocure: Hexvix/Cysview demonstrates long term benefit
Results from 5.5 year follow up of recurrence of bladder cancer
This clinical study includes retrospective follow up from 526 patients included in a prospective randomized Phase III trial in 28 centers in EU and North America. The results from this Phase III study were published in Journal of Urology November 2010 by Stenzl et al. In this 5.5 year follow- up study data were collected related to additional bladder cancer recurrences after they had completed the prospective Phase III trial.
The results (Intention to Treat) showed that fewer patients who received Hexvix experienced recurrence of their bladder cancer compared to patients who did not receive Hexvix, e.g. 38% in the Hexvix group versus 31.8% in the group that did not receive Hexix had no recurrence during the 5.5 year observation period. A statistically significant difference was observed between the recurrence free survival curves, p=0.04.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.